Beijing SL Pharmaceutical Co Ltd (002038) — Cash Flow Reinvestment Rate
Beijing SL Pharmaceutical Co Ltd (002038) has a Cash Flow Reinvestment Rate of 0.17x as of September 2025, reinvesting CN¥11.35 Million (capex CN¥11.35 Million ) from operating cash flow of CN¥66.55 Million. Check 002038 cash flow quality score to evaluate the quality of earnings relative to operating cash generation.
Reinvestment Rate
Total Reinvested
Operating Cash Flow
Capital Expenditures
Beijing SL Pharmaceutical Co Ltd Cash Flow Reinvestment Rate (2003–2025)
Historical reinvestment intensity for Beijing SL Pharmaceutical Co Ltd across 23 annual periods. Explore Beijing SL Pharmaceutical Co Ltd (002038) long-term investment share to see how much of total assets are deployed in long-term investments.
Annual Cash Flow Reinvestment Rate for Beijing SL Pharmaceutical Co Ltd (2003–2025)
Year-by-year capital reinvestment analysis for Beijing SL Pharmaceutical Co Ltd. For live market cap and broader valuation context, see 002038 stock market capitalisation.
| Year | Reinvestment Rate | Total Reinvested (CNY) | Operating CF | Capex | YoY Change |
|---|---|---|---|---|---|
| 2025 | 1.03x | CN¥265.61 Million | CN¥257.66 Million | CN¥192.97 Million | ▼ -33.1% |
| 2024 | 1.54x | CN¥347.57 Million | CN¥225.49 Million | CN¥347.38 Million | ▲ +160.9% |
| 2023 | 0.59x | CN¥271.93 Million | CN¥460.20 Million | CN¥218.36 Million | ▼ -67.3% |
| 2022 | 1.81x | CN¥703.89 Million | CN¥389.82 Million | CN¥163.49 Million | ▲ +252.7% |
| 2021 | 0.51x | CN¥237.87 Million | CN¥464.63 Million | CN¥236.91 Million | ▼ -73.9% |
| 2020 | 1.96x | CN¥816.62 Million | CN¥415.84 Million | CN¥255.95 Million | ▲ +238.9% |
| 2019 | 0.58x | CN¥385.77 Million | CN¥665.83 Million | CN¥272.78 Million | ▼ -37.8% |
| 2018 | 0.93x | CN¥451.84 Million | CN¥485.17 Million | CN¥227.37 Million | ▼ -23.1% |
| 2017 | 1.21x | CN¥460.83 Million | CN¥380.72 Million | CN¥229.65 Million | ▼ -34.6% |
| 2016 | 1.85x | CN¥734.87 Million | CN¥396.86 Million | CN¥164.21 Million | ▲ +109.2% |
| 2015 | 0.89x | CN¥446.93 Million | CN¥504.87 Million | CN¥129.68 Million | ▲ +172.6% |
| 2014 | 0.32x | CN¥151.01 Million | CN¥465.00 Million | CN¥151.01 Million | ▲ +3.1% |
| 2013 | 0.32x | CN¥109.48 Million | CN¥347.41 Million | CN¥109.48 Million | ▼ -49.3% |
| 2012 | 0.62x | CN¥247.89 Million | CN¥398.60 Million | CN¥247.89 Million | ▲ +94.6% |
| 2011 | 0.32x | CN¥73.05 Million | CN¥228.59 Million | CN¥73.05 Million | ▲ +76.8% |
| 2010 | 0.18x | CN¥43.04 Million | CN¥238.13 Million | CN¥43.04 Million | ▲ +3.5% |
| 2009 | 0.17x | CN¥30.46 Million | CN¥174.41 Million | CN¥30.46 Million | ▲ +43.7% |
| 2008 | 0.12x | CN¥23.61 Million | CN¥194.32 Million | CN¥23.61 Million | ▼ -59.7% |
| 2007 | 0.30x | CN¥26.61 Million | CN¥88.36 Million | CN¥26.61 Million | ▼ -73.3% |
| 2006 | 1.13x | CN¥64.95 Million | CN¥57.55 Million | CN¥64.95 Million | ▼ -34.0% |
| 2005 | 1.71x | CN¥81.24 Million | CN¥47.48 Million | CN¥81.24 Million | ▲ +201.6% |
| 2004 | 0.57x | CN¥17.73 Million | CN¥31.26 Million | CN¥17.73 Million | ▲ +5.5% |
| 2003 | 0.54x | CN¥16.43 Million | CN¥30.55 Million | CN¥16.43 Million | — |